Lilly’s Donanemab Set For Broad Indication, No Tau PET Imaging Condition Following US FDA Panel Nod

 
• By Sue Sutter

The advisory committee also hails the treatment-to-amyloid clearance approach used in the Phase III trial as innovative, but questions how it should apply in clinical practice.

Smooth sailing
It was smooth sailing for Lilly's donanemab at an FDA advisory committee meeting. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers